Industry

Positive biomarker data confirmed in additional subjects and at additional timepoints Stable or continuously increasing cognitive, language and motor functions observed in patients treated at ≤31 months of age, including subjects with SGSH mutations associated with the severe disease phenotype Full data analysis in Q3 2022 before discussions with regulatory authorities on next steps PARIS–(BUSINESS … [Read more…]

The oversubscribed first close of Series B funding was led by Cathay Health, joined by Credit Mutuel Innovation, Kurma Partners and BNP Paribas Développement. Funds will accelerate the execution of the Company’s product development towards a new standard of care for knee replacement interventions. PARIS–(BUSINESS WIRE)–#biotech—Ganymed Robotics, a developer of computer vision software and robotics … [Read more…]

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion’s management in three scientific conferences in July 2022. Laurent Desire, Ph.D., Sensorion’s … [Read more…]

Elevate Care calls on area healthcare partners to make $5,000 matching donations SKOKIE, Ill.–(BUSINESS WIRE)–#HealthcarePartnersforHighlandPark–Healthcare operators and partners across Chicagoland are coming together to help Aiden McCarthy, a 2-year-old boy who lost both of his parents in the Highland Park 4th of July parade shooting. Using #HealthcarePartnersforHighlandPark, Elevate Care started this movement feeling the desire … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its novel targeted protein degrader ICP-490 for the treatment of multiple myeloma (MM) and … [Read more…]

– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential – ALAMEDA, Calif. & KRAKOW, Poland–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) and Ryvu Therapeutics S.A. (“Ryvu”) (Warsaw Stock Exchange: RVU) today announced that the companies have entered into … [Read more…]

A sub-analysis of the Phase 3 LIVE-AIR study of lenzilumab showed a strong correlation between C-reactive protein (CRP) and outcomes with lenzilumab treatment with the greatest clinical benefit experienced by patients with baseline CRP<150 mg/L In these patients, likelihood of survival without mechanical ventilation (SWOV) was achieved in 90% of LIVE-AIR patients treated with lenzilumab … [Read more…]

iHealthScreen is the first company that developed the late AMD prediction model and was awarded a patent by USPTO NEW YORK–(BUSINESS WIRE)–#AI—iPredictTM late AMD prediction model provides a fully automated prediction score for age-related macular degeneration (AMD), and identifies the individuals who are at risk of developing late AMD in 1 year, 2-year or 5-year. … [Read more…]

AHF Press Teleconference: Thurs., July 7 @ 11:00 am PT With case numbers increasing rapidly in L.A. and elsewhere and extremely limited vaccine doses available nationwide, AHF will call on the Los Angeles County Department of Public Health to ramp up public education on the virus and its prevention, as well as share surveillance data … [Read more…]

CAN106 Phase 1 results showed rapid and potent C5 inhibition, complete and sustained blockade of complement activity Data presented at European Hematology Association 2022 Congress and 14th International Conference on Complement Therapeutics CAN106 in Phase 1b/2 study of paroxysmal nocturnal hemoglobinuria in China Shows potential for treating other complement-mediated diseases BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge … [Read more…]